carbamates has been researched along with Amentia in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function." | 9.10 | Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. ( Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H, 2003) |
| "65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks." | 9.10 | A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. ( Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M, 2002) |
| "Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD)." | 7.72 | Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. ( Hartmann, S; Möbius, HJ, 2003) |
| "The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition." | 5.31 | Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. ( Bullock, R; Cameron, A, 2002) |
| " We studied the effects of rivastigmine on the qEEG in Parkinson's disease (PD) patients with dementia." | 5.10 | Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. ( Fogelson, N; Giladi, N; Kogan, E; Korczyn, AD; Neufeld, MY; Shabtai, H, 2003) |
| "Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function." | 5.10 | Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. ( Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H, 2003) |
| "65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks." | 5.10 | A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. ( Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M, 2002) |
| " Pitolisant, a novel histamine-3 receptor antagonist/inverse agonist, gained approval for the treatment of excessive daytime sleepiness in adults with narcolepsy as well as obstructive sleep apnea." | 5.05 | New pharmacologic agents for insomnia and hypersomnia. ( Earl, DC; Van Tyle, KM, 2020) |
| "Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD)." | 3.72 | Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. ( Hartmann, S; Möbius, HJ, 2003) |
| "Cholinesterase inhibitors (ChEIs) are dosed in two phases for the treatment of dementia, an initial dose-escalation phase to achieve a therapeutic dose and a maintenance phase where the therapeutic dose is given for long-term therapy." | 2.41 | The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. ( Inglis, F, 2002) |
| " Rivastigmine shows a clear dose-response relationship, and physicians should aim to maintain patients on doses of 6 mg/day or higher, to a maximum of 12 mg/day." | 2.41 | The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. ( Bullock, R, 2002) |
| "The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition." | 1.31 | Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. ( Bullock, R; Cameron, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Earl, DC | 1 |
| Van Tyle, KM | 1 |
| Lin, JN | 1 |
| Lin, CL | 1 |
| Lin, MC | 1 |
| Lai, CH | 1 |
| Lin, HH | 1 |
| Yang, CH | 1 |
| Kao, CH | 1 |
| Rösler, M | 1 |
| Inglis, F | 1 |
| Bullock, R | 2 |
| Cameron, A | 1 |
| Hartmann, S | 1 |
| Möbius, HJ | 1 |
| Fogelson, N | 1 |
| Kogan, E | 1 |
| Korczyn, AD | 3 |
| Giladi, N | 2 |
| Shabtai, H | 2 |
| Neufeld, MY | 1 |
| Werber, EA | 1 |
| Gandelman-Marton, R | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| GIBBS, AE | 1 |
| WYKES, PR | 1 |
| D AMELIO, V | 1 |
| ANNOVI, G | 1 |
| Fuchsberger, T | 1 |
| Möller, HJ | 1 |
| Hampel, H | 1 |
| Gurevich, T | 1 |
| Benbunan, B | 1 |
| Anca, M | 1 |
| Schneider, LS | 1 |
| Smith, DJ | 1 |
| Yukhnevich, S | 1 |
| Weiser, M | 1 |
| Rotmensch, HH | 1 |
| Hartman, R | 1 |
| Cicin-Sain, A | 1 |
| Anand, R | 1 |
| Tewfik, GI | 1 |
| Jain, VK | 1 |
| Harcup, M | 1 |
| Magowan, S | 1 |
7 reviews available for carbamates and Amentia
| Article | Year |
|---|---|
New pharmacologic agents for insomnia and hypersomnia.
Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans; | 2020 |
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Topics: Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans | 2002 |
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Topics: Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Nootropic A | 2002 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli | 2003 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
Understanding changes in cholinergic function: implications for treating dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibi | 2002 |
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Dementia; Hum | 2002 |
5 trials available for carbamates and Amentia
| Article | Year |
|---|---|
Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Dementia; Elec | 2003 |
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; De | 2003 |
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Cognition; Dementia; Humans; Male; Parkinson Disease; P | 2003 |
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Dementia; D | 2002 |
Effectiveness of various tranquilisers in the management of senile restlessness.
Topics: Aged; Carbamates; Chlorpromazine; Clinical Trials as Topic; Dementia; Female; Haloperidol; Humans; H | 1970 |
7 other studies available for carbamates and Amentia
| Article | Year |
|---|---|
Increased Risk of Dementia in Patients With Acute Organophosphate and Carbamate Poisoning: A Nationwide Population-Based Cohort Study.
Topics: Adult; Aged; Carbamates; Cohort Studies; Dementia; Female; Humans; Incidence; Insecticides; Insuranc | 2015 |
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Dementia; Female; Hallucinations; Humans; Male; Parkins | 2002 |
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Res | 2003 |
The use of methylpentynol carbamate in a geriatric unit.
Topics: Carbamates; Dementia; Geriatrics; Humans; Mental Disorders; Psychotic Disorders | 1960 |
Sedation in geriatrics using methylpentynol carbamate.
Topics: Aged; Carbamates; Dementia; Geriatrics; Humans; Hypnotics and Sedatives; Mental Disorders; Psychotic | 1960 |
[TREATMENT WITH MEBUTAMATE (AN ANTIHYPERTENSIVE WITH CENTRAL ACTION) OF MENTAL PATIENTS WITH HYPERTENSIVE MANIFESTATIONS].
Topics: Alcoholism; Antihypertensive Agents; Anxiety; Bipolar Disorder; Carbamates; Dementia; Epilepsy; Huma | 1963 |
Adverse reactions to rivastigmine in three cases of dementia.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Alzheimer Disease; Carbamates; Cholinesterase Inhi | 2001 |